P/E ratio for Emergent BioSolutions (EBS)
P/E ratio as of September 2023 (TTM): -0.2707
According to Emergent BioSolutions 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.270695. At the end of 2021 the company had a P/E ratio of 10.0.
P/E ratio history for Emergent BioSolutions from 2007 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 10.0 | -35.24% |
| 2020 | 15.5 | -69.54% |
| 2019 | 50.9 | 7.32% |
| 2018 | 47.4 | 99% |
| 2017 | 23.8 | -16.55% |
| 2016 | 28.6 | 14.2% |
| 2015 | 25.0 | -11.84% |
| 2014 | 28.4 | 6.11% |
| 2013 | 26.7 | 8.33% |
| 2012 | 24.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 8.48 | -3,233.30% | 🇺🇸 USA |
 Merck MRK | 85.7 | -31,752.93% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 4.47 | -1,751.93% | 🇬🇧 UK |
 Soligenix SNGX | -0.0929 | -65.67% | 🇺🇸 USA |
 SIGA Technologies SIGA | 13.2 | -4,980.22% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -11.0 | 3,980.53% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -5.11 | 1,787.73% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.